Back to top

Analyst Blog

Regeneron Pharmaceuticals Inc. (REGN - Analyst Report) is developing fourteen human monoclonal antibodies, utilizing its VelocImmune technology. The company is developing seven of the antibodies in partnership with Sanofi (SNY - Analyst Report). One of the most interesting candidates being developed under the partnership is alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody.

The companies presented encouraging data on the candidate from a multi-center phase II study (n~100) in Japanese patients. Data revealed that treatment with alirocumab (as a combination therapy) resulted in significant reduction in low-density lipoprotein-cholesterol (LDL-C or bad cholesterol) across three doses (150 mg, 75 mg and 50 mg) compared to patients treated with placebo.

At week 12, average LDL reduction was observed to be 72% at 150 mg, 62% at 75 mg and 55% at the 50 mg dosage. The average LDL reduction in the placebo cohort was found to be only 3%.

We remind investors that in Oct 2013, Sanofi and Regeneron reported encouraging top-line data from the phase III ODYSSEY MONO (n=103) on alirocumab. The randomized, double-blind, active-controlled, parallel-group study is evaluating the efficacy and safety of alirocumab as a monotherapy over 24 weeks in patients suffering from primary hypercholesterolemia (presence of high cholesterol levels in the blood). The patients stand a moderate risk of being affected by cardiovascular diseases. Regeneron/Sanofi commenced enrolling patients in 2 other studies on alirocumab ODYSSEY CHOICE I and CHOICE II (as part of the ODYSSEY phase III program) in the final quarter of 2013 and the first quarter of 2014, respectively.

We note that Amgen (AMGN - Analyst Report) recently reported positive phase III data on its cholesterol fighter evolocumab (AMG 145), also a PCSK9 inhibitor.  

Regeneron carries a Zacks Rank #3 (Hold). Sanofi holds a Zacks Rank #4 (Sell).  An example of a better-ranked stock is Alexion Pharmaceuticals (ALXN - Analyst Report) carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%